Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
Papamichael K, Cheifetz AS, Melmed GY, Irving PM, Vande Casteele N, Kozuch PL, Raffals LE, Baidoo L, Bressler B, Devlin SM, Jones J, Kaplan GG, Sparrow MP, Velayos FS, Ullman T, Siegel CA. Papamichael K, et al. Among authors: velayos fs. Clin Gastroenterol Hepatol. 2019 Aug;17(9):1655-1668.e3. doi: 10.1016/j.cgh.2019.03.037. Epub 2019 Mar 27. Clin Gastroenterol Hepatol. 2019. PMID: 30928454 Free PMC article.
Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update.
Rubin DT, Cruz-Correa MR, Gasche C, Jass JR, Lichtenstein GR, Montgomery EA, Riddell RH, Rutter MD, Ullman TA, Velayos FS, Itzkowitz S; 5-ASA in Colorectal Cancer Prevention Meeting Group. Rubin DT, et al. Among authors: velayos fs. Inflamm Bowel Dis. 2008 Feb;14(2):265-74. doi: 10.1002/ibd.20297. Inflamm Bowel Dis. 2008. PMID: 17932965 Review.
Timing of myelosuppression during thiopurine therapy for inflammatory bowel disease: implications for monitoring recommendations.
Lewis JD, Abramson O, Pascua M, Liu L, Asakura LM, Velayos FS, Hutfless SM, Alison JE, Herrinton LJ. Lewis JD, et al. Among authors: velayos fs. Clin Gastroenterol Hepatol. 2009 Nov;7(11):1195-201; quiz 1141-2. doi: 10.1016/j.cgh.2009.07.019. Epub 2009 Jul 22. Clin Gastroenterol Hepatol. 2009. PMID: 19631285 Free PMC article.
The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all.
Melmed GY, Spiegel BM, Bressler B, Cheifetz AS, Devlin SM, Harrell LE, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Siegel CA. Melmed GY, et al. Among authors: velayos fs. Clin Gastroenterol Hepatol. 2010 Aug;8(8):655-9. doi: 10.1016/j.cgh.2010.04.023. Epub 2010 May 6. Clin Gastroenterol Hepatol. 2010. PMID: 20451665
Setting priorities for comparative effectiveness research in inflammatory bowel disease: results of an international provider survey, expert RAND panel, and patient focus groups.
Cheifetz AS, Melmed GY, Spiegel B, Talley J, Devlin SM, Raffals L, Irving PM, Jones J, Kaplan GG, Kozuch P, Sparrow M, Velayos F, Baidoo L, Bressler B, Siegel CA. Cheifetz AS, et al. Inflamm Bowel Dis. 2012 Dec;18(12):2294-300. doi: 10.1002/ibd.22920. Epub 2012 Feb 15. Inflamm Bowel Dis. 2012. PMID: 22337359
95 results